<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939663</url>
  </required_header>
  <id_info>
    <org_study_id>EMMMElshahed</org_study_id>
    <nct_id>NCT03939663</nct_id>
  </id_info>
  <brief_title>Role of Vaginal Misoprostol Prior to IUCD Insertion in Women Who Delivered Only by Elective Caesarean Section.</brief_title>
  <official_title>Role of Vaginal Misoprostol Prior to IUCD Insertion in Women Who Delivered Only by Elective Caesarean Section.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Role of vaginal misoprostol prior to IUCD insertion in women who delivered only by elective
      caesarean section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Misoprostol ( 400mcg ) vaginally administrated 3 hours prior to IUCD insertion increases the
      ease and success of insertion and decrease associated pain among women who had delivered only
      by elective caesarean section.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of failed IUCD insertions regardless of the reason .</measure>
    <time_frame>during insertion</time_frame>
    <description>pain reported by particiepant during insertion graded from 1 to 10 on visual analogue scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the degree of difficulty of the IUCD insertion .</measure>
    <time_frame>during insertion</time_frame>
    <description>Judged as the resistance of the internal cervical os experienced by the investigator and measured by a 5-point scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>heavy bleeding</measure>
    <time_frame>7 days</time_frame>
    <description>heavy bleeding and blood clots</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial or total expulsion</measure>
    <time_frame>4 to 6 weeks</time_frame>
    <description>not insitu by U/S</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>IUD Insertion Complication</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets vaginally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mcg vaginally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>misoprostol 2 tablets</description>
    <arm_group_label>misoprostol group</arm_group_label>
    <other_name>misotac</other_name>
    <other_name>cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>starch pills manufactured to mimic misoprostol 200 mg tablets</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women will be 20 to 40 years of age.

          -  Desires IUCD placement and able to participate.

          -  Negative pregnancy test.

          -  Willing to follow- up in 6-8 weeks for a standard IUCD follow-up visit.

          -  Delivered only by cesarean section.

        Exclusion Criteria:

          -  Active cervical infection.

          -  Current pregnancy.

          -  Uterine anomaly.

          -  Fibroid uterus.

          -  Copper allergy/Wilson's disease.

          -  Undiagnosed abnormal uterine bleeding.

          -  Cervical or uterine cancer.

          -  Allergy to misoprostol.

          -  Previous vaginal delivery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>enas mahmoud, MBBCh</last_name>
    <phone>01096448037</phone>
    <phone_ext>01122742293</phone_ext>
    <email>enasmahmoud957@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Enas Mahmoud</name>
      <address>
        <city>Cairo</city>
        <zip>9999</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>enas mahmoud, MBBCh.</last_name>
      <phone>01096448037</phone>
      <phone_ext>01096448037</phone_ext>
      <email>enasmahmoud957@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 4, 2019</study_first_submitted>
  <study_first_submitted_qc>May 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>May 4, 2019</last_update_submitted>
  <last_update_submitted_qc>May 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Enas Mahmoud Mohammed Mohammed Elshahed</investigator_full_name>
    <investigator_title>MBBCh.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

